Sonelokimab
Based on 1 Customer Validation
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.81%
- CAS No.: 1414386-05-2
- 분자량:40.11 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
VH-VH'-VH, trivalent
Human
|
IL-17A |
IL-17F |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A collagen-induced arthritis model in cynomolgus monkey[4]
-
Dosage:2.8 and 10 mg/kg
-
Administration:weekly intervals for 8 consecutive weeks
-
Result:Significantly improved X-ray score B and the arthritis score in a collagen-induced arthritis model in cynomolgus monkey.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH'-VH, trivalent
ELISA, FACS, Functional assay
-
Loaded IL-17F Protein, Human (HEK293, His, HY-P70540) on NTA biosensor, can bind Sonelokimab with an affinity constant of 2.859E-10 M as determined in BLI assay. -
Loaded IL-17A (HEK293, His, HY-P70527) on NTA biosensor, can bind Sonelokimab with an affinity constant of <1.000E-11 M as determined in BLI assay.
Chemical Information
-
CAS No. 1414386-05-2
-
Appearance Liquid
-
분자량 40.11 kDa
-
Color Colorless to light yellow
-
SMILES
[Sonelokimab]
-
Synonyms
ALX 0761; M 1095
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Torres T, et al. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016 Jul;25(7):751-4. [Content Brief]
[2]. Rossotti MA, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022 Jul;289(14):4304-4327. [Content Brief]
[3]. Gao W, et al. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis. Front Immunol. 2023 May 25;14:1151977. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sonelokimab Related Classifications
HY-P99397 Related Classifications
Powered by Bioz